Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology [1][4] - The company will present updates on its recent milestones and research at the BIO International Convention 2025, highlighting advancements in wound healing, multiple sclerosis, and psoriasis [1][2] Company Overview - FibroBiologics holds over 275 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [4] - The company aims to transform the treatment landscape for chronic diseases by addressing underlying biological dysfunction rather than merely managing symptoms [2][4] Upcoming Events - The presentation at the BIO International Convention is scheduled for June 17, 2025, at 10:45 a.m. ET, at the Boston Convention & Exhibition Center [2] - The company is set to begin a Phase 1/2 clinical trial for diabetic foot ulcers later this year, marking a significant step in its research efforts [2]
FibroBiologics to Present at the BIO International Convention 2025